A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• A diagnosis of recurrent or refractory DLBCL.

• Adequate organ functions.

• Able to swallow capsules.

Exclusion Criteria:

• More than 3 prior treatments for this disease.

• Serious heart problems.